← Evidence map

ArticlePharmacoEconomics2018

Response to 'Comment on ''Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy"'.

Amir Ansaripour et al.PubMed ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Response to 'Comment on ''Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy"'. | OpenQuestion